MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Timing And Type Of Adverse Events Following Long-Term Treatment With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Infusion – Data From The ELEGANCE Interim Analysis

    N. Smith, B. Amlani (Reading, United Kingdom)

    Objective: To evaluate the type and timing of occurrence of treatment-emergent adverse events (AEs) in people with advanced Parkinson’s disease (PD) following up to one…
  • 2025 International Congress

    Unraveling the Variability in Amantadine Response for Levodopa-Induced Dyskinesias: The Impact of Clinical and Genetic Factors

    L. Saadatpour, H. Chaparro-Solano, J. Yu, C. Sonneborn, C. Piccinin, S. Anis, E. Assaedi, P. Coss, S. Horn, O. Vaou, I. Mata, H. Fernandez (San Antonio, USA)

    Objective: To identify demographic, clinical, and genetic factors associated with the outcomes of amantadine treatment in dyskinetic Parkinson’s disease (PD) patients. Background: While recent advancements…
  • 2025 International Congress

    IncobotulinumtoxinA to Treat Sialorrhea in Parkinson’s Disease: a Real-life Study: 6-year Interim Results

    B. Bergmans, N. Winter, V. Schotte, N. Sys, E. van Massenhove, G. Pollet, H. Couckuyt, L. Delameilleure, M. van Zandijcke (Bruges, Belgium)

    Objective: We evaluate the long-term efficacy and safety of incobotulinumtoxinA injections in advanced Parkinson’s disease (PD) patients suffering from sialorrhea. Background: Sialorrhea is frequently a…
  • 2025 International Congress

    Combining Machine Learning and Linear Mixed Models to Estimate Medication Effect in People with Parkinson’s Disease

    A. Castro Mejia, S. Sapienza, L. Pavelka, R. Kruger, J. Klucken (Belvaux, Luxembourg)

    Objective: To estimate medication effect, as the score difference between MDS-UPDRS III in OFF and ON-state, using a minimal set of clinical features. Background: The…
  • 2025 International Congress

    Patient And Clinician Perceptions Of Disease Improvement With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) In Advanced Parkinson’s – Data From The ELEGANCE Interim Analysis

    N. Smith, B. Amlani (Reading, United Kingdom)

    Objective: To evaluate clinicians’ and patients’ views of the level of improvement in Parkinson’s disease (PD) achieved following up to two years of treatment with…
  • 2025 International Congress

    Comparing the Impact of Levodopa versus Pramipexole on Eye-Tracking Parameters in Treatment-Naïve Parkinson’s Disease: A Longitudinal Study

    Z. Kosutzka, L. Hapakova, I. Straka, A. Kusnirova, M. Minar (Bratislava, Slovakia)

    Objective: To investigate the differential effects of levodopa versus pramipexole on eye-tracking parameters in treatment-naïve patients with Parkinson's disease. Background: Parkinson's disease (PD) is characterized…
  • 2025 International Congress

    A novel virtual home-safety fall prevention program for Parkinson’s Disease

    M. Afshari, V. Palakuzhy, G. Jones, A. Hernandez, B. Ouyang, C. Goetz (Chicago, USA)

    Objective: To determine the feasibility and preliminary efficacy of a novel virtually-delivered protocol targeting extrinsic environmental fall risk factors in the homes of persons with…
  • 2025 International Congress

    Modeling Levodopa Resistance in Parkinson’s Disease: A Novel Approach Targeting Locus Coeruleus Degeneration

    A. Goel, R. Goel (Bathinda, India)

    Objective: To develop a Parkinson’s disease (PD) model replicating levodopa (LD) resistance by incorporating degeneration of both the substantia nigra (SN) and locus coeruleus (LC),…
  • 2025 International Congress

    SL-START: A Multicentre Observational Study of Sublingual Apomorphine Titration and Usage Schemes in Routine Practice

    J. Kassubek, P. Themann, H. Brigas, C. Maganete, G. Harrison-Jones, I. Pijuan Jiménez (Ulm, Germany)

    Objective: A patient’s early experience with a new medication is critical to medication adherence and overall treatment outcomes. The SL-START study aims to characterize how…
  • 2025 International Congress

    Efficacy of Combined Transcranial Direct Current Stimulation (tDCS) and Gait Training on Gait in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    A. Hegazi, H. Hussein, R. Mohamed (Mansoura, Egypt)

    Objective: To evaluate the effects of addition of tDCS to gait training  on gait parameters and motor function in individuals with Parkinson’s disease Background: Gait…
  • « Previous Page
  • 1
  • …
  • 322
  • 323
  • 324
  • 325
  • 326
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley